NASDAQ:BCYC Bicycle Therapeutics (BCYC) Stock Price, News & Analysis → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Free BCYC Stock Alerts $22.88 +0.31 (+1.37%) (As of 12:41 PM ET) Add Compare Share Share Today's Range$22.35▼$22.8850-Day Range$17.42▼$26.1052-Week Range$12.54▼$28.91Volume83,321 shsAverage Volume378,888 shsMarket Capitalization$687.32 millionP/E RatioN/ADividend YieldN/APrice Target$46.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Bicycle Therapeutics alerts: Email Address Bicycle Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside108.0% Upside$46.86 Price TargetShort InterestBearish8.46% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 6 Articles This WeekInsider TradingSelling Shares$126,139 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($5.20) to ($5.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.03 out of 5 starsMedical Sector556th out of 910 stocksPharmaceutical Preparations Industry254th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingBicycle Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBicycle Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.46% of the outstanding shares of Bicycle Therapeutics have been sold short.Short Interest Ratio / Days to CoverBicycle Therapeutics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Bicycle Therapeutics has recently decreased by 0.78%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBicycle Therapeutics does not currently pay a dividend.Dividend GrowthBicycle Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCYC. Previous Next 2.4 News and Social Media Coverage News SentimentBicycle Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Bicycle Therapeutics this week, compared to 4 articles on an average week.Search Interest5 people have searched for BCYC on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $126,139.00 in company stock.Percentage Held by Insiders10.20% of the stock of Bicycle Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($5.20) to ($5.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bicycle Therapeutics is -4.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bicycle Therapeutics is -4.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBicycle Therapeutics has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Bicycle Therapeutics Stock (NASDAQ:BCYC)Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Read More BCYC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCYC Stock News HeadlinesApril 7, 2024 | insidertrades.comNicholas Keen Sells 790 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) StockApril 21, 2024 | americanbankingnews.comBicycle Therapeutics (NASDAQ:BCYC) Stock Price Down 5.8%April 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 20, 2024 | americanbankingnews.comBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up to $21.82April 19, 2024 | forbes.comThe Bicycle Day Dream Bike: A Carbon Fiber Hommage To Albert HofmannApril 18, 2024 | msn.comNCDOT Bicycle Helmet Initiative to begin soonApril 18, 2024 | yahoo.comLebanon Bicycle Recycle gears up annual Spring Fling hoping to give away 100 bikes to kidsApril 14, 2024 | investing.comBicycle therapeutics executive sells shares to cover tax withholding obligationsApril 23, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.April 12, 2024 | msn.comThe Bicycle Bakery in Camden Road, Tunbridge Wells closes after owner opens up about health problems but hopes to reopen in summerApril 12, 2024 | msn.com38th annual Redlands Bicycle Classic kicks off with women's division making strides in the sportApril 11, 2024 | msn.com‘Bicycle nazis’: Winnipeg city councillor taking heat after committee meeting commentApril 11, 2024 | msn.comThe Bicycle Bakery: Award-winning Tunbridge Wells bakery that had queues down the street to closeApril 9, 2024 | msn.comLA Once Had A Bicycle Freeway. What Happened To 1900's Cyclist Dream?April 9, 2024 | markets.businessinsider.comBicycle Therapeutics: Strong Buy on Breakthrough Preclinical Data, Clinical Progress, and Robust Financial HealthApril 7, 2024 | investing.comBicycle therapeutics executive sells shares worth over $3,600April 6, 2024 | ca.news.yahoo.comPeterborough Bicycle Advisory Committee gets in gear for spring cycling summitApril 4, 2024 | usnews.comGaza's Wasteland Seen Via Bicycle After Six Months of WarApril 2, 2024 | finance.yahoo.comBicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 27, 2024 | msn.comTrek’s New Wahoo Path Hybrid Kids Line Helps Create Life-Long Bicycle RidersMarch 21, 2024 | bizjournals.comRed Bicycle coffee shop in The Nations temporarily closed due to fire damageMarch 19, 2024 | msn.comTake a cool bike ride at Icicle BicycleMarch 17, 2024 | msn.comTrek Bicycle in Little Rock holds grand reopening after March 31 tornado destroyed original locationMarch 16, 2024 | msn.comRiverbend Bicycle Club, Clinton, hosts annual rideMarch 16, 2024 | finance.yahoo.comBCYC Apr 2024 12.500 callMarch 16, 2024 | finance.yahoo.comBCYC Apr 2024 22.500 callMarch 16, 2024 | finance.yahoo.comBCYC Apr 2024 20.000 putSee More Headlines Receive BCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today4/23/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BCYC CUSIPN/A CIK1761612 Webwww.bicycletherapeutics.com Phone441223261503FaxN/AEmployees284Year FoundedN/APrice Target and Rating Average Stock Price Target$46.86 High Stock Price Target$65.00 Low Stock Price Target$32.00 Potential Upside/Downside+104.8%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($5.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-180,660,000.00 Net Margins-669.72% Pretax Margin-664.32% Return on Equity-57.80% Return on Assets-34.14% Debt Debt-to-Equity Ratio0.08 Current Ratio8.08 Quick Ratio8.08 Sales & Book Value Annual Sales$26.98 million Price / Sales25.47 Cash FlowN/A Price / Cash FlowN/A Book Value$12.35 per share Price / Book1.85Miscellaneous Outstanding Shares30,040,000Free Float26,979,000Market Cap$687.32 million OptionableOptionable Beta0.89 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Kevin Lee M.B.A. (Age 56)Ph.D., CEO & Executive Director Comp: $1.31MMr. Lee H. Kalowski M.B.A. (Age 43)President Comp: $879.99kSir Gregory Paul Winter CBE (Age 73)FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder & Non-Executive Director Comp: $55kMr. Alistair Milnes (Age 50)Chief Operating Officer Comp: $796.09kDr. Michael Skynner B.sc. Ph.d. (Age 54)Ph.D., Chief Technology Officer Comp: $881.01kDr. Christian HeinisScientific FounderMs. Alethia Rene Young (Age 45)Chief Financial Officer Mr. Travis ThompsonSenior VP, Chief Accounting Officer & Principal Accounting OfficerDr. Nicholas Keen Ph.D. (Age 55)Chief Scientific Officer Mr. Zafar QadirGeneral CounselMore ExecutivesKey CompetitorsAerovate TherapeuticsNASDAQ:AVTELongboard PharmaceuticalsNASDAQ:LBPHY-mAbs TherapeuticsNASDAQ:YMABPharming GroupNASDAQ:PHARORIC PharmaceuticalsNASDAQ:ORICView All CompetitorsInsiders & InstitutionsMichael Charles Ferguso HannaySold 257 sharesTotal: $5,779.93 ($22.49/share)Woodstock CorpBought 3,502 shares on 4/9/2024Ownership: 0.083%Kevin LeeSold 3,158 sharesTotal: $75,191.98 ($23.81/share)Michael SkynnerSold 955 sharesTotal: $22,738.55 ($23.81/share)Nicholas KeenSold 790 sharesTotal: $18,809.90 ($23.81/share)View All Insider TransactionsView All Institutional Transactions BCYC Stock Analysis - Frequently Asked Questions Should I buy or sell Bicycle Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BCYC shares. View BCYC analyst ratings or view top-rated stocks. What is Bicycle Therapeutics' stock price target for 2024? 7 analysts have issued 1 year price objectives for Bicycle Therapeutics' shares. Their BCYC share price targets range from $32.00 to $65.00. On average, they expect the company's share price to reach $46.86 in the next year. This suggests a possible upside of 108.0% from the stock's current price. View analysts price targets for BCYC or view top-rated stocks among Wall Street analysts. How have BCYC shares performed in 2024? Bicycle Therapeutics' stock was trading at $18.08 at the beginning of the year. Since then, BCYC shares have increased by 24.6% and is now trading at $22.53. View the best growth stocks for 2024 here. When is Bicycle Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our BCYC earnings forecast. How were Bicycle Therapeutics' earnings last quarter? Bicycle Therapeutics plc (NASDAQ:BCYC) posted its earnings results on Tuesday, February, 20th. The company reported ($1.16) earnings per share for the quarter, beating analysts' consensus estimates of ($1.23) by $0.07. The firm had revenue of $5.33 million for the quarter, compared to the consensus estimate of $11.68 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 57.80% and a negative net margin of 669.72%. What ETFs hold Bicycle Therapeutics' stock? ETFs with the largest weight of Bicycle Therapeutics (NASDAQ:BCYC) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Harbor Health Care ETF (MEDI).Harbor Disruptive Innovation ETF (INNO). What other stocks do shareholders of Bicycle Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC). When did Bicycle Therapeutics IPO? Bicycle Therapeutics (BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Bicycle Therapeutics' major shareholders? Bicycle Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Woodstock Corp (0.08%). Insiders that own company stock include Alistair Milnes, Kate Bingham, Kevin Lee, Lee Kalowski, Michael Charles Ferguso Hannay, Michael Skynner, Nicholas Keen, Nigel Crockett, Pierre Legault, Stephen B Alexander and Travis Alvin Thompson. View institutional ownership trends. How do I buy shares of Bicycle Therapeutics? Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCYC) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
